2 Information about ivosidenib

Marketing authorisation indication


Ivosidenib (Tibsovo, Servier) monotherapy is indicated for 'the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy'.

Dosage in the marketing authorisation



The list price of a 60‑tablet pack of 250 mg ivosidenib is £12,500 (excluding VAT; BNF online, accessed October 2023).


The company has a commercial arrangement. This makes ivosidenib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)